Navigation Links
Enrollment Underway in CLARITY-AF Study to Compare Efficacy, Safety and Efficiency of Two Catheter Ablation Technologies

WATERLOO, Belgium, July 8, 2010 /PRNewswire/ -- Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study ("CLARITY-AF"), comparing the efficacy, safety and efficiency of CARTO(R) 3 System guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation ( ID NCT01116557) (

This prospective, multi-center, randomized (2:1), controlled, two-arm clinical study will enroll up to 350 patients at up to 15 sites throughout Europe. Patients in this study will be followed for one year after ablation. The study is intended to test the hypothesis that the NAVISTAR(R) THERMOCOOL(R) catheter using the CARTO(R) 3 System is superior to fluoroscopy-guided PVAC(R) for efficacy and safety and will demonstrate non-inferiority for efficiency comparing the NAVISTAR(R) THERMOCOOL(R) catheter used with the CARTO(R) 3 System to the PVAC(R) catheter. Interim results from the study will be disclosed after completion of the enrollment phase and the final results will be available at the end of the 1-year follow up period.

"The CLARITY-AF trial is the first multi-center randomized trial comparing atrial fibrillation ablation devices. This trial will compare the Medtronic PVAC(R) catheter to the Biosense Webster NAVISTAR(R) THERMOCOOL(R) catheter. Primary endpoints are freedom from any atrial fibrillation, atrial tachycardia, pulmonary vein stenosis and procedure time. Given the growing epidemic of atrial fibrillation, the results of this trial will guide optimal treatment in a large patient population" said Prof. Mattias Duytschaever from AZ St Jan Hospital in Bruges, Belgium, and principal investigator of the CLARITY-AF study.

With this study Biosense Webster shows its commitment to working towards a cure for atrial fibrillation and improving the quality of life of patients suffering from this disease. Atrial fibrillation is the most prevalent heart rhythm disorder, increasing in prevalence with age. Clinical data suggests that 20% of all strokes result from the illness, which often remains undiagnosed and which can increase the risk of a stroke fivefold.

"The CLARITY-AF study will rigorously evaluate the efficacy, safety and efficiency of the Biosense Webster NAVISTAR(R) THERMOCOOL(R) catheter with CARTO(R) 3 System guidance compared to the Medtronic Pulmonary Vein Ablation catheter(R) (PVAC(R)) with fluoroscopy for treating paroxysmal atrial fibrillation. With enrollment now started, we are confident that this scientific study will demonstrate objective results that will show the superiority of the NAVISTAR(R) THERMOCOOL(R) catheter system for treating atrial fibrillation", according to Shlomi Nachman, World Wide President of Biosense Webster. "We look forward to releasing the early results next year."

CARTO(R) 3 is the third generation of the CARTO(R) electro-anatomical mapping system, which brings the technology to an unprecedented level of performance. The system has been designed based on the feedback provided by several of the most prominent Key Opinion Leaders in the atrial fibrillation treatment arena. CARTO(R) 3 is built on the core magnetic based CARTO(R) proprietary technology, which has been recognized as the gold standard in its domain, with a special focus on increased performance, ease of use and Electrophysiology-lab efficiency.

The NAVISTAR(R) THERMOCOOL(R) catheter, manufactured by Biosense Webster, Inc. is one of the most widely adopted catheters for the treatment of atrial fibrillation in Europe, and the only ablation catheter approved by the U.S. Food and Drug Administration for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with CARTO(R) Navigation Systems.

According to data which appeared earlier this year in JAMA (Journal of American Medical Association, January 2010), patients with a common heart rhythm disorder, called atrial fibrillation, who were treated with catheter ablation using the NAVISTAR(R) THERMOCOOL(R) catheter, demonstrated significantly better outcomes at one year compared to those receiving drug therapy. In addition, the patients treated with catheter ablation reported markedly fewer symptoms and substantially improved quality of life.

About Biosense Webster, Inc.

Biosense Webster, Inc., a Johnson & Johnson company, pioneered electrophysiology diagnostic catheters more than 30 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic and mapping tools. As one of the leaders in navigation systems and ablation therapy, Biosense Webster, Inc.'s technology includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. With its proprietary products the company is changing the way electrophysiologists diagnose and treat arrhythmias.

The third party trademarks used herein are trademarks of their respective owners

    Ulrike Domany
    Director Public Affairs & Communication

SOURCE Biosense Webster, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
2. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
3. Cellectar Completes Enrollment in Phase I Clinical Trial of Lead Drug Candidate (131)I-CLR1404 for the Treatment of Solid Malignancies
4. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
5. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
6. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
7. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
8. Dune Medical Completes Enrollment in MarginProbe(TM) Pivotal Trial for Real-Time Detection of Cancer During Breast Conservation Surgery
9. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
10. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
11. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Post Your Comments:
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... changing the way that they are handling security in light of the recent terrorist ... presence in an attempt to stop an attack from reaching U.S. soil. Especially around ...
(Date:11/27/2015)... ... 27, 2015 , ... "When I was traveling, I was ... N.J. "Many people catch diseases simply from sitting on such dirty toilet seats. ... from germs." , He developed the patent-pending QUDRATECS to eliminate the need to ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health ... both STEMI and Sepsis conditions present in similar ways and require time-critical intervention to ...
Breaking Medicine News(10 mins):